A phase I investigation of the sequential use of methotrexate and paclitaxel with and without G-CSF for the treatment of solid tumors

Annals of Oncology

Volumn 7, Issue 1, 1996, Pages 59-63

  Huber, M H ^a   Lee, J S ^a   Newman, R A ^b   Fossella, F V ^a   Wester, M ^a   Ki Hong, W ^a   Lippman, S M ^a,c  

^a UNIVERSITY OF TEXAS   (United States)

^b Clin Pharmacology Resource Facility   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Methotrexate; Paclitaxel; Phase I; Solid tumors

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; PACLITAXEL;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR;

EID: 0030069958     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010479     Document Type: Article

References (22)

1. McGuire WP, Rowinsky EK, Rosenshein NB et al. Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989; 111: 273-9.
2. Holmes FA, Walters RS, Theriault RL et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991; 83: 1797-805.
3. Chang A, Kim K, Glick J et al. Phase II study of Taxol, Mebarone, and Piroxantrone in stage IV non-small cell lung cancer: The Eastern Cooperative Oncology Group Results. J Natl Cancer Inst 1993; 85: 388-94.
4. Murphy WK, Fossella FV, Winn RJ et al. Phase U study of taxol in patients with non-small cell lung cancer. J Natl Cancer Inst 1993; 85: 384-8.
5. Forastiere AA. Use of paclitaxel (taxol) in squamous cell carcinoma of the head and neck. Semin Oncol 1993; 20: 56-60.
6. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med 1995; 332: 1004-14.
7. Bertino JR, Romanini A. Folate antagonists. In Holland JF, Frei E, Bast RC et al. (eds): Cancer Medicine. Philadelphia, PA: Lea Febiger 1993; 698-711.
8. Tishler RB, Geard RB, Hall EJ, Schiff PB. Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 1992; 52: 3495-7.
9. Verde F, Berrez J, Antomy C, Karsenti E. Taxol-induced microtubule asters in mitotic extracts of Yenopus eggs: Requirement of phosphorylated factors and cytoplasmic dynein. J Cell Biol 1991; 112: 1177-87.
10. Fuchs DA, Johnson RK. Cytologic evidence that taxol, an anti-neoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison. Cancer Treat Rep 1978; 62: 1219-22.
11. Jordan MA, Toso RJ, Thorwer D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 1993; 90: 9552-6.
12. Liebmann JE, Cook JA, Lipschultz C et al. Cytotoxic studies of paclitaxel (Taxol) in human tumor cell lines. Br J Cancer 1993; 68: 1104-9.
13. Chou TC, Otter GM, Sirotnak FM. Combined effects of edatrexate with taxol or taxotere against breast cancer cell growth. Proc Am Assoc Cancer Res 1993; 34: 300 (Abstr).
14. Srosy G, Kahn E, Stone DA et al. Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 1992; 10: 1165-70.
15. Ajani JA, Welch SR, Raber MN et al. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 1990; 8: 147-59.
16. Newman RA, Fuentes A, Minor TY et al. Determination of echinomycin (NSC-526417) in human plasma: A comparison of conventional HPLC to capillary HPLC combined with electrospray ionization and mass spectrometry. J Liquid Chromatogr 1994; 17: 403-17.
17. Vokes EE, Weichselbaum RR, Lippman SM et al. Head and neck cancer. N Engl J Med 1993; 328: 184-94.
18. Murphy WK, Winn RJ, Huber M et al. Phase II study of taxol in patients with non-small cell lung cancer who have failed platinum containing chemotherapy. Proc Am Soc Clin Oncol 1994; 13: 1224 (Abstr).
19. Ruckdeschel J, Wagner H, Williams C et al. Second-line chemotherapy for resistant, metastatic non-small cell lung cancer: The role of taxol. Proc Am Soc Clin Oncol 1994; 13: 357 (Abstr).
20. Gianni L, Kearns CM, Giani A et al. Non-linear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/ pharmacodynamic relationships in humans. J Clin Oncol 1995; 13: 180-90.
21. Ohtsu T, Sasaki Y, Tamura T et al. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: A 3-hour infusion versus a 24-hour infusion. Clin Cancer Res 1995; 1: 599-606.
22. Huber MH, Hong WK, Hittelman WN. Microtubule changes in human tumor samples following in vivo and ex vivo paclitaxel exposure. Proc Am Assoc Cancer Res 1994; 35: 212.